免疫治疗在胃癌、食管癌和胃食管交界处癌中的当前作用——来自加拿大西部胃肠癌共识会议的报告。
Current Role of Immunotherapy in Gastric, Esophageal and Gastro-Esophageal Junction Cancers-A Report from the Western Canadian Gastrointestinal Cancer Consensus Conference.
机构信息
Cross Cancer Institute, Alberta Health Services, Edmonton, AB T6G 1Z2, Canada.
British Columbia Cancer Agency, Vancouver, BC V5Z 4E6, Canada.
出版信息
Curr Oncol. 2022 Apr 29;29(5):3160-3170. doi: 10.3390/curroncol29050257.
Gastric, esophageal and gastro-esophageal junction cancers are associated with inferior outcomes. For early-stage disease, perioperative chemotherapy or chemoradiation followed by surgery is the standard treatment. For most patients with advanced upper gastrointestinal tract cancers, platinum-based chemotherapy remains a standard treatment. Recently, several randomized clinical trials have demonstrated the benefit of immunotherapy involving checkpoint inhibitors alone or in combination with chemotherapy in patients with gastro-esophageal cancer and have changed the treatment landscape. The Western Canadian Gastrointestinal Cancer Consensus Conference (WCGCCC), involving experts from four Western Canadian provinces, convened virtually on 16 June 2021 and developed the recommendations on the role of immunotherapy in patients with gastro-esophageal cancer.
胃、食管和胃食管交界处癌症的预后较差。对于早期疾病，围手术期化疗或放化疗后手术是标准治疗。对于大多数晚期上消化道癌症患者，含铂化疗仍然是标准治疗。最近，几项随机临床试验表明，免疫疗法（单独或联合化疗）对胃食管癌患者有益，并改变了治疗格局。由来自加拿大四个西部省份的专家组成的加拿大西部胃肠癌共识会议（WCGCCC）于 2021 年 6 月 16 日以虚拟形式召开会议，制定了免疫疗法在胃食管癌患者中的作用的建议。
Zotero 插件